We find that FZD4/LRP5 agonists alleviate BRB dysfunction and completely resolve CE, highlighting that norrin/FZD4 signaling is a highly suitable target for pharmacological intervention in ME. This evidence concerns the gene FZD4 and cholesteryl ester measurement.